CAR-MA therapy development integrates chimeric antigen receptor engineering with macrophage-based immunotherapy to target solid tumors. This approach enhances tumor infiltration, antigen-specific phagocytosis, and immune modulation, offering a one-stop solution for cell sourcing, vector design, functional validation, and preclinical evaluation.
